Clinical Development

BD acquires Atto Bioscience

BD acquires Atto Bioscience

BD Biosciences has acquired Atto Bioscience in a deal worth $25
million (€20m), allowing it to enter the emerging high content cell
analysis market and enhancing its presence in the pharmaceutical
and biotechnology sectors.